Patient satisfaction at 24 months after treatment for localized prostate cancer

The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. … READ MORE …

Prostvac in the treatment of prostate cancer: an update

As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. … READ MORE …

LAST CHANCE to participate in our current survey

By late yesterday nearly 600 men had completed our recent survey and most of them had expressed some degree of interest in participating in the quality of life trial we will be initiating soon. Again, thanks to all of you who have done that. … READ MORE …

The treatment of mCRPC with a combination of docetaxel + enzalutamide

We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …

PLEASE consider completing our recent survey!

So just over 300 patients have already completed the survey that we put up on line last Friday. Thanks to all of you who have done that. And we’d really like to see if we can get to a total of something like 750 “with a little help from our friends”. … READ MORE …

A new study (and new technology) about quality of life and prostate cancer

Prostate Cancer International and two of its partners — CancerLife and the John Wayne Cancer Institute in Santa Monica, CA — are soon going to be looking for men to participate in a new clinical trial about quality of life and living with prostate cancer. … READ MORE …

Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …